Making its second appearance on our one to watch lists, Leeds spin-out Tissue Regenix returns after a successful launch in the US.
Tissue Regenix
Institution: Leeds University
Sector: Regenerative Tissue
Marking its second outing, Leeds spin-out Tissue Regenix yet again makes it onto our spin-outs to watch list after a year of establishing itself in the US market.
Driving Regenix’s move to the states is its dCell technology. In the US, chronic wounds (ie. Wounds that take over three months to heal – some of which never heal) affect up to 6.5 million people, with healthcare costs running in excess of $25bn. The burdens of such a wound, physical, mental, and financial, make them crippling for a person to deal with. Tissue Regenix aims to alleviate the condition. Its biological scaffolding technology dCell has shown great promise in healing the wounds. 87% of patients treated have seen a reduction in their wounds, with 60% seeing the wounds healed entirely.
The company has now established several commercial partnerships in the US to utilise the technology, and is turning its focus to clinical trials in the EU.
